BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20201055)

  • 1. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group.
    Dworzak MN; Gaipa G; Schumich A; Maglia O; Ratei R; Veltroni M; Husak Z; Basso G; Karawajew L; Gadner H; Biondi A
    Cytometry B Clin Cytom; 2010 May; 78(3):147-53. PubMed ID: 20201055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].
    Pawińska-Wasikowska K; Balwierz W
    Przegl Lek; 2010; 67(6):361-5. PubMed ID: 21344762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.
    Gaipa G; Basso G; Maglia O; Leoni V; Faini A; Cazzaniga G; Bugarin C; Veltroni M; Michelotto B; Ratei R; Coliva T; Valsecchi MG; Biondi A; Dworzak MN;
    Leukemia; 2005 Jan; 19(1):49-56. PubMed ID: 15538405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
    Gaipa G; Basso G; Aliprandi S; Migliavacca M; Vallinoto C; Maglia O; Faini A; Veltroni M; Husak D; Schumich A; Ratei R; Biondi A; Dworzak MN;
    Cytometry B Clin Cytom; 2008 May; 74(3):150-5. PubMed ID: 18271020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
    Cáp J; Babusíková O; Kaiserová E; Jamárik M
    Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
    Muzzafar T; Medeiros LJ; Wang SA; Brahmandam A; Thomas DA; Jorgensen JL
    Am J Clin Pathol; 2009 Nov; 132(5):692-8. PubMed ID: 19846809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
    Chen JS; Hsiao CC; Sheen JM; Cheng CN
    Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.